On August 31, 2026, Orexo AB issued a press release announcing a non-binding agreement in principle to settle a Department of Justice investigation that has been running since 2020. The company would pay USD 4 million in installments over several years, plus a capped contingent payment of five percent of net sales tied to sales thresholds in 2030 and 2031. The release names no specific statute violated. It describes no conduct. It identifies no patient harmed, no prescriber improperly influenced, no marketing material that crossed a legal line. Six years of federal investigation, and the public record is a number and a phrase: “opioid marketing.” That is not transparency. That is its own story.
The DOJ has been watching Orexo since 2020. Six years is a long time. For context, the DOJ’s criminal and civil resolution against Endo Health Solutions, which involved the opioid Opana ER with INTAC, resulted in $1.536 billion in criminal fines and civil settlements and came with a detailed factual recitation of exactly how Endo’s sales force was trained to minimize the drug’s abuse potential in physician conversations. Orexo’s press release contains none of that. Which raises a specific operational question: what did Orexo’s marketing apparatus for Zubsolv, its buprenorphine/naloxone sublingual tablet for opioid use disorder, actually do between 2020 and now that warranted six years of federal scrutiny?
What Six Years of Silence Conceals
The DOJ investigation opened in 2020, the same year Zubsolv was Orexo’s primary commercial product in the U.S. market. Buprenorphine products occupy a peculiar regulatory position: they are Schedule III controlled substances prescribed to treat opioid dependence, meaning the line between legitimate promotion and off-label or misleading marketing carries direct public-health consequences. An aggressive sales representative overstating Zubsolv’s superiority to Suboxone, or understating diversion risk, is not a minor compliance incident. It is a clinical harm vector.
Orexo’s own regulatory record during this period is not clean. The FDA issued a second Complete Response Letter for OX124, Orexo’s high-dose naloxone nasal spray for opioid overdose reversal, marking the second rejection in 15 months for the same application. Two CRLs on the same product in 15 months signals a sponsor that is either submitting inadequate data packages or failing to execute FDA’s feedback from the first rejection, sometimes both. Neither reflects an operation with exceptional regulatory discipline. And a company navigating simultaneous FDA rejections and a DOJ opioid-marketing investigation is, by definition, an operation under stress at multiple compliance nodes at once.
Stress at multiple nodes is exactly when the rot in standard operating procedures becomes visible. A sales compliance function that is stretched, or underfunded, or culturally subordinated to revenue targets, will not catch a field representative making a claim that goes three sentences past the approved label. A medical affairs function that is siloed from legal review will approve promotional slide decks with efficacy language that does not survive a 21 CFR Part 202 analysis. None of this requires malice. It requires a sponsor that decided, at some point, that commercial urgency outweighed the overhead of rigorous promotional review. The DOJ investigation suggests that calculus was made.
The non-binding nature of this agreement deserves its own scrutiny. “Non-binding agreement in principle” is legal language for: we have agreed on the shape of a deal but nothing is final. Settlements structured this way sometimes collapse. They sometimes expand when discovery surfaces new conduct during the finalization period. They almost never result in a smaller payment than the one announced. For Orexo, the contingent payment structure tied to 2030 and 2031 net sales thresholds is particularly telling: the DOJ accepted a deal where part of the penalty is conditional on commercial success that has not yet occurred. That is a structurally unusual accommodation, and it suggests Orexo’s negotiators successfully argued that a fixed penalty above $4 million would threaten the company’s viability. Whether the DOJ’s acceptance of that argument was appropriate requires knowing the magnitude of the underlying conduct, which the press release does not tell you.
The Indictment the Press Release Refuses to Write
Orexo was founded in 1995 in Uppsala, Sweden, and built its U.S. commercial presence substantially on Zubsolv. The opioid use disorder market is not a market where promotional misconduct is a technical violation. It is a market where a prescriber who is misled about a buprenorphine product’s risk profile makes a prescribing decision that affects a patient in active addiction recovery. The downstream harm of that decision is not an abstract compliance cost. It is a relapse, a lost job, a family crisis, or worse.
The DOJ knows this. The agency has been aggressive about naming specific conduct in opioid settlements precisely because the public-health stakes justify transparency. The Endo resolution named the training scripts. The Purdue Pharma resolution named the sales territories and the physician targets. The Mallinckrodt resolution, which involved $1.6 billion, named the specific claims made about abuse-deterrent formulations. Orexo’s settlement announcement names nothing. That is not because nothing happened. Investigations do not run for six years on a hunch. The absence of named conduct in a voluntary press release means Orexo chose not to disclose it, and no final court order yet compels them to.
That gap is where FOIA requests and court-docket monitoring become mandatory tools. Clinical operations executives at any company that partnered with Orexo in a commercial or co-promotion capacity between 2020 and 2026 should be pulling those records now. If the DOJ’s eventual formal settlement agreement, once finalized, identifies specific promotional practices, those practices may have touched shared commercial infrastructure. The compliance liability does not stop at Orexo’s organizational boundary.
What Sponsors Must Do Before the Final Order Lands
The structural read here is not complicated, but it is uncomfortable. The opioid-marketing enforcement wave that consumed Purdue, Endo, Mallinckrodt, and AmerisourceBergen did not end because regulators ran out of targets. It decelerated because the largest actors were resolved. Orexo, as a smaller Swedish specialty pharma with a single major U.S. opioid-class asset, represents exactly the type of secondary actor that enforcement attention reaches after the headline cases close. There are likely others. Any sponsor running a buprenorphine, methadone, or extended-release naltrexone commercial program in the U.S. during the early 2020s should treat this settlement as a signal to conduct a proactive promotional-practices audit before a CID arrives.
For sponsors in or adjacent to the opioid-class commercial space: commission an independent review of your promotional review committee records from 2019 through 2024. Not a legal-privilege review designed to protect the company. An operational audit designed to find what a DOJ attorney would find. The difference between a $4 million settlement and a $1.5 billion settlement is almost never the underlying conduct. It is how early a company found the problem and how credibly it could demonstrate corrective action before the government came in the door.
For FDA-watchers: the moment the Orexo settlement agreement is finalized and filed, the conduct description in that document will be the most important opioid-marketing compliance data point of 2026. If the DOJ buries it in a consent decree with minimal public docketing, file the FOIA request the same day. The public deserves to know what six years of investigation found, not just what Orexo’s communications team chose to include in a press release timed to a Monday news cycle.
The next test of the system is the finalized settlement document itself, which must survive DOJ approval and, if structured as a False Claims Act resolution, requires court filing that creates a public record. Watch the docket. The contingent payment clause tied to 2030 and 2031 sales thresholds means this case will not be fully closed for another five years, and every Zubsolv sales quarter between now and then is a data point in a federally supervised commercial compliance story that Orexo has not yet fully told.
References
- PR Newswire / Orexo AB — “Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice” (August 31, 2026)
- Orexo AB — Official press release, DOJ settlement agreement in principle, terms and contingent payment structure
- U.S. Department of Justice — “Opioid Manufacturer Endo Health Solutions Inc. Ordered to Pay $1.536B in Criminal Fines and Civil Settlements”
- Fierce Pharma — “FDA gives another thumbs down to Orexo’s nasal spray for opioid overdose” (second CRL for OX124)
- Orexo AB — Corporate history and product platform overview
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
